Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine

European Journal of Nuclear Medicine

Volumn 26, Issue 10, 1999, Pages 1363-1378

  Cook, Gary J R ^a,b   Maisey, Michael N ^a   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

8 Fluoro 2 deoxyglucose; Artefacts; Carbon 11 methionine; Pitfalls

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

ARTIFACT; DIAGNOSTIC ACCURACY; DRUG ACCUMULATION; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; REVIEW;

ANIMALS; ARTIFACTS; CARBON RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; METHIONINE; RADIOPHARMACEUTICALS; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032885033     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050597     Document Type: Review

References (74)

1. Cook GJR, Fogelman I, Maisey M. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose position emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 24: 308-314.
2. Warburg O. On the origin of cancer cells. Science 1954; 123: 306-314.
3. Strauss LG. Fluorine-18 deoxyglucose and false positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-1415.
4. Yamamoto T, Seino Y, FuLomoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T, Imura H. Overexpression of facultative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-230.
5. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumour and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992; 183: 643-647.
6. 18FDG, thymidine, L-methionine and L-leucine. J Nucl Med 1997; 38: 382-386.
7. Torizuka T, Fisher SJ, Wahl RL. Insulin induced hypoglycaemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology 1997; 203: 169-172.
8. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996; 23: 941-946.
9. 18FDG uptake in hyperglycaemia. J Nucl Med 1996; 37: 1713-1717.
10. Knuuti MJ, Maki M, Yki-Jarvinen H, et al. The effect of insulin and FFA on myocardial glucose uptake. J Mol Cell Cardiol 1995; 27: 1359-1367.
11. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal human. Eur J Nucl Med. 1993; 20: 308-318.
12. 18FDG-SPET studies in patients with non-insulin dependent diabetes mellitus during hyperinsulinaemic euglycaemic clamping. Nucl Med Commun 1997; 18: 200-206.
13. Huitink JM, Visser FC, van Leeuwen GR, et al. Influence of high and low plasma insulin levels on the uptake of fluorine-18 fluorodeoxyglucose in myocardium and femoral muscle assessed by planar imaging. Eur J Nucl Med 1995; 22: 1141-1148.
14. 18F-FDG-PET. Experiences with the euglycaemic hyper-insulinaemic clamp technique. Angiology 1995; 46: 313-320.
15. 18FDG-PET. J Nucl Med 1995; 36: 456-463.
16. Bax JJ, Veening MA, Visser FC, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging: a comparative study using different protocols. Eur J Nucl Med 1997; 24: 35-41.
17. Barrington SF, Maisey MM. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 1996; 37: 1127-1129.
18. Engel H, Steinen H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441-446.
19. Bischof delalove A, Wahl RL. How high a level of FDG abdominal activity is considered normal? J Nucl Med 1995; 36: 106P.
20. 18FDG uptake in the gastrointestinal tract. Can it be reduced? J Nucl Med 1999; 40: 22P-23P.
21. Picard Y, Thompson CJ. Motion correction of PET images using multiple acquisition frames. IEEE Trans Med Imaging 1997; 16: 137-144.
22. 18FDG. J Nucl Med 1995; 36: 484-492.
23. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1-3.
24. Knopp MV, Bischoff HG. Evaluation of pulmonary lesions with positron emission tomography. Radiologe 1994; 34: 588-591.
25. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38: 1575-1583.
26. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J. Timothy AR. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-3346.
27. 18FDG-PET for assessment of adrenal masses for metastatic disease [abstract]. J Nucl Med 1996; 37: 141P.
28. 18FDG uptake vary in normal lung? [abstract] J Nucl Med 1995; 36: 4P.
29. Cook GJR, Maisey M, Fogelman I. Paget's disease of bone: appearances with 18-FDG PET. J Nucl Med 1997; 38: 1495-1497.
30. Hanson PS, Ponto LLB, Kirchner PT, et al. Diagnostic accuracy of F-18 FDG whole body PET imaging in oncologic patients [abstract] J Nucl Med 1995; 36: 193P.
31. Bicik I, Bauerfeind P, Breitbach T, von Schulthess GK, Fried M. Inflammatory bowel disease activity measured by positron emission tomography. Lancet 1997; 350: 262.
32. Ishiwata K, Enomoto K, Sasaki T, et al. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med 1996; 37: 279-285.
33. 11C]methionine. Proc Natl Acad Sci USA 1996; 93: 1841-1846.
34. 11C]methionine. Int J Radial Appl Instrum 1988; 15: 123-126.
35. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumour tissues be measured in vivo? J Nucl Med 1993; 34: 1936-1943.
36. Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Uemura K. Indications for differential diagnosis of nontumour central nervous system diseases from tumours. A positron emission tomography study. J Neuroimaging 1997; 7: 8-15.
37. 11C]methionine and rubidium-82 using PET. J Neurol Sci 1995; 132: 20-27.
38. Roelcke U, Radu EW, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of rubidium and C-methionine uptake in brain tumours measured by positron emission tomography. J Neurooncol 1996; 27: 163-171.
39. Ogawa T, Hatazawa J. Inugami A, et al. Carbon-11-methionine PET evaluation of intracerebral haematoma: distinguishing neoplastic from non-neoplastic haematoma. J Nucl Med 1995; 36: 2175-2179.
40. Dethy S, Manto M, Kentos A, et al. PET findings in a brain abscess associated with a silent atrial septal defect. Clin Neurol Neurosurg 1995; 97: 349-353.
41. Lindholm P, Leskinen-Kallio S, Kirvela O, et al. Head and neck cancer: effect of food ingestion on uptake of C-11 methionine. Radiology 1994; 190: 863-867.
42. Bergstrom M, Ericson K, Hagenfeldt L, et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr 1987; 11: 208-213.
43. 18FDG in cultured cancer cells. J Nucl Med 1996; 37: 502-506.
44. 11C-methionine). Am J Neuroradiol 1996; 17: 345-353.
45. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993; 186: 45-53.
46. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39: 778-785.
47. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50: 1316-1322.
48. 11C-methionine for diagnosis of recurrent brain tumour and radiation injury. Acta Radiol 1991; 32: 197-202.
49. Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. PET and CT in differential diagnosis between recurrent and residual glioma and treatment induced brain lesions. Acta Radiol 1989; 30: 121-128.
50. Sundin A, Johansson C, Hellman P et al. PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. J Nucl Med 1996; 37: 1766-1770.
51. 11C-methionine in hyperpararthyroidism. Surgery 1994; 116: 974-981.
52. 11C]Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998; 139: 195-197.
53. Rodriguez M, ReLn S, Ahlstrohm H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
54. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32: 1211-1218.
55. Nuutinen J. Leskinen S, Lindholm P, et al. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med 1998; 25: 729-735.
56. 11C-methionine in breast cancer studied by PET. An association with the size of S phase fraction. Br J Cancer 1991; 1121-1124.
57. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 1993; 67: 789-791.
58. Jansson T, Westlin JE, Ahlstrohm H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation. J Clin Oncol 1995; 13: 1470-1477.
59. Fujiwara T, Matsuzawa T, Kubota K, et al. Relationship between histologic type of primary lung cancer and carbon-11-methionine uptake with PET. J Nucl Med 1989; 30: 33-37.
60. Miyazawa H, Arai T, Lio M, Hara T. PET imaging of non-small cell lung carcinoma with carbon-11-methionine; relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993; 1886-1891.
61. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumour with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-1932.
62. 11C]methionine: a preliminary study. Eur J Nucl Med 1993; 20: 495-501.
63. Ahlstrohm H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996; 37: 180-185.
64. 11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the bladder. Br J Urol 1994; 74: 767-774.
65. Lapela M, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med 1994; 35: 1618-1623.
66. Lapela M, Leskinen-Kallio S, Varpula M, et al. Metabolic imaging of ovarian tumours with carbon-11-methionine: a PET study. J Nucl Med 1995; 36: 2196-2200.
67. Lindholm P, Leskinen-Kallio S, Minn H et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 1993; 34: 1711-1716.
68. 11C]methionine. Int J Radiat Oncol Biol Phys 1995; 32: 787-794.
69. Lindholm P, Leskinen-Kallio S, Nagren K, et al. Carbon-11-methionine PET imaging in malignant melanoma. J Nucl Med 1995; 36: 1806-1810.
70. 18F]fluorodeoxyglucose in brain tumours. A powerful diagnostic and prognostic tool. Invest Radial 1987; 22: 360-371.
71. 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radial 1987; 28: 673-681.
72. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1997; 25: 79-83.
73. Chen CC, Skarulis MC, Fraker DL, Alexander HR, Marx SJ, Spiegel AM. Technetium-99m-sestamibi imaging before reoperation for primary hyperparathyroidism. J Nucl Med 1995; 36: 2186-2191.
74. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorode-oxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39: 1160-1166.